News

Vertex posts additional trial data for type 1 diabetes therapy
Vertex Pharmaceuticals (NASDAQ:VRTX) has posted new data from a Phase 1/2/3 study for zimislecel (VX-880), its experimental ...
Zacks Investment Research on MSN22h
Here's Why Vertex Pharmaceuticals (VRTX) Fell More Than Broader Market
In the latest close session, Vertex Pharmaceuticals (VRTX) was down 1.68% at $440.87. The stock fell short of the S&P 500, which registered a loss of 0.22% for the day. Meanwhile, the Dow gained 0.08% ...
Investing Snacks1d
Vertex Earnings Surge, But Valuation Raises Eyebrows
Vertex Pharmaceuticals has been making quiet waves lately, popping up on investors’ radars like a biotech whack-a-mole. With ...
Google Messages update brings long-awaited RCS chat improvements
Google Messages has started rolling out the new features Google announced last week, including support for custom RCS group ...
Citi's 'accelerating' its AI strategy with new leaders. Here's how they're readying the firm for a new future.
Citi is consolidating its AI strategy behind three key leaders. They're also eying a push into the next generation of the ...